إعلان
إعلان

NPCE

NPCE logo

Neuropace, Inc. Common Stock

16.75
USD
برعاية
-0.21
-1.24%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

16.95

+0.20
+1.16%

تقارير أرباح NPCE

النسبة الإيجابية المفاجئة

NPCE تفوق 12 من 19 آخر التقديرات.

63%

التقرير التالي

بيانات التقرير القادم
٠٢ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$24.92M
/
-$0.18
التغير الضمني من Q3 25 (Revenue/ EPS)
-8.90%
/
+63.64%
التغير الضمني من Q4 24 (Revenue/ EPS)
+16.08%
/
--

Neuropace, Inc. Common Stock earnings per share and revenue

On ٠٤ نوفمبر ٢٠٢٥, NPCE reported earnings of -0.11 USD per share (EPS) for Q3 25, beating the estimate of -0.20 USD, resulting in a 45.05% surprise. Revenue reached 27.35 مليون, compared to an expected 25.13 مليون, with a 8.86% difference. The market reacted with a +38.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 المحللين forecast an EPS of -0.18 USD, with revenue projected to reach 24.92 مليون USD, implying an زيادة of 63.64% EPS, and نقصان of -8.90% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
٠٦ يناير ٢٠٢٦ إلى ربع سنوي2 26
تقدير
-$0.10
الفعلي
$0.00
مفاجئة
+100.00%
الأسئلة الشائعة
For Q3 2025, Neuropace, Inc. Common Stock reported EPS of -$0.11, beating estimates by 45.05%, and revenue of $27.35M, 8.86% above expectations.
The stock price moved up 38.09%, changed from $9.40 before the earnings release to $12.98 the day after.
The next earning report is scheduled for ٠٢ مارس ٢٠٢٦.
Based on 10 المحللين, Neuropace, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $24.92M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان